Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, announced terms for its IPO on Tuesday.
The London, United Kingdom-based company plans to raise $200 million by offering 13.3 million ADSs at a price range of $14 to $16. At the midpoint of the proposed range, Orchard Therapeutics would command a fully diluted market value of $1.4 billion.
Orchard Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol ORTX. J.P. Morgan, Goldman Sachs and Cowen are the joint bookrunners on the deal. It is expected to price during the week of October 29, 2018.
